Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Fluid bed processes: drying, granulating, and coating in just one product container
Subscribe To Our Newsletter & Stay Updated